UCB Pharma, Raleigh, USA.
Oregon Health and Science University, Portland, USA.
Clin Exp Rheumatol. 2018 Mar-Apr;36(2):263-274. Epub 2017 Nov 14.
The incidence and prevalence of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic (nr-)axSpA, have been investigated in multiple populations, though there is a paucity of population-level data. Here, we identify population-based studies in AS and nr-axSpA, and describe the methodologic challenges in conducting these, outlining potential reasons for disparate incidence and prevalence estimates.
PubMed and Embase were searched for population-based studies providing incidence and prevalence rates, published in English from 1 Jan 2000-30 Jun 2015. Extracted information included incidence/prevalence rates, geographical population, study design, data source, case definition, age/gender, and classification criteria used.
Of 2,148 articles identified, 19, from 15 countries, fulfilled eligibility criteria. Incidence rates per 100,000 patient-years were reported in 4 AS studies and varied from 0.4 (Iceland) to 15.0 (Canada). Reported AS prevalence rates per 100,000 persons also showed considerable variation (16 studies: 6.5 [Japan] to 540.0 [Turkey]). Only 3 axSpA and no nr-axSpA prevalence rates were reported. Considerable variation was seen in the methodology used to estimate incidence and prevalence rates, e.g. screening method, study design, and classification criteria. Although the prevalence of AS is known to vary by HLA-B27 status, only 4 studies reported this genetic marker.
There is an unmet need for future studies to use consistent methodology, capture all relevant information (including HLA-B27 positivity), and investigate under-reported populations (e.g. nr-axSpA; southern hemisphere countries) to estimate the population burden of axSpA. Future studies should aim to address data gaps to provide accurate incidence/prevalence estimates for the global axSpA population.
轴性脊柱关节炎(axSpA)的发病率和患病率,包括强直性脊柱炎(AS)和非放射学(nr-)axSpA,已经在多个人群中进行了研究,尽管人群水平的数据很少。在这里,我们确定了 AS 和 nr-axSpA 的基于人群的研究,并描述了进行这些研究的方法学挑战,概述了发病率和患病率估计值差异的潜在原因。
在 PubMed 和 Embase 中搜索了 2000 年 1 月 1 日至 2015 年 6 月 30 日发表的基于人群的研究,提供发病率和患病率率,用英文发表。提取的信息包括发病率/患病率率、地理人群、研究设计、数据源、病例定义、年龄/性别和使用的分类标准。
在 2148 篇文章中,有 19 篇来自 15 个国家,符合入选标准。有 4 项 AS 研究报告了每 10 万患者年的发病率,发病率从冰岛的 0.4 到加拿大的 15.0 不等。也有 16 项研究报告了每 10 万人的 AS 患病率存在很大差异(日本为 6.5,土耳其为 540.0)。仅报告了 3 项 axSpA 和无 nr-axSpA 患病率。用于估计发病率和患病率的方法学存在很大差异,例如筛选方法、研究设计和分类标准。尽管 AS 的患病率已知因 HLA-B27 状态而异,但只有 4 项研究报告了这种遗传标记。
未来的研究需要使用一致的方法,收集所有相关信息(包括 HLA-B27 阳性),并调查报告不足的人群(例如 nr-axSpA;南半球国家),以估计 axSpA 的人群负担。未来的研究应旨在解决数据差距,为全球 axSpA 人群提供准确的发病率/患病率估计。